Table 1.
Patient and disease characteristics
| Characteristic | Overall, n (%) | Evaluable, n (%) |
|---|---|---|
| Number of patients (%) | 29 (100) | 23 (100) |
| Sex | ||
| Male | 14 (48) | 11 (48) |
| Female | 15 (52) | 12 (52) |
| Age, y | ||
| Median | 75 | 75 |
| Range | 49-84 | 49-84 |
| ECOG Performance Status | ||
| 0-1 | 22 (76) | 17 (74) |
| >1 | 7 (24) | 6 (26) |
| Ann Arbor stage | ||
| 1-2 | 2 (7) | 2 (9) |
| 3-4 | 27 (93) | 21 (91) |
| LDH | ||
| Normal | 6 (21) | 5 (22) |
| Elevated | 23 (79) | 18 (78) |
| Bone marrow involvement | ||
| Yes | 7 (24) | 6 (26) |
| No | 5 (17) | 4 (17) |
| Unknown | 17 (59) | 13 (57) |
| PTCL subtypes | ||
| AITL | 16 (55) | 14 (61) |
| PTCL-NOS | 10 (34) | 6 (26) |
| ATLL | 2 (7) | 2 (9) |
| EATL | 1 (3) | 1 (4) |
| IPI risk category | ||
| 0-1 | 1 (3) | 1 (4) |
| 2 | 6 (21) | 6 (26) |
| 3-5 | 22 (76) | 16 (70) |
EATL, enteropathy-associated T-cell lymphoma; ECOG, Eastern Clinical Oncology Group; IPI, international prognostic index; LDH, lactate dehydrogenase.